The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogeneous real-world patient population. Additional data on the efficacy and safety of ibalizumab and its impact on patient reported outcomes will be captured until study end.

Primary Objective:

To evaluate the long-term efficacy, safety, and durability of ibalizumab in combination with other ARVs by comparing the virologic, immunologic and clinical outcomes of patients receiving ibalizumab treatment versus patients not receiving ibalizumab.

A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People ≥ 16 Years of Age Who Have Sex With Male Partners and Are at Risk for HIV Infection

Explore BIOS Clinical Research.

A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens

A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

People living with HIV are 50–100% more likely to develop heart disease (including heart attack and stroke) than people without HIV. REPRIEVE is a clinical research trial exploring long-term prevention of heart disease among people living with HIV. Call: 1-877-29-HEART Leah Lane 760-834-7949

Clinicians at Eisenhower Medical Center continue to take part in groundbreaking research, including: interventional cardiology, orthopedics, novel biotherapies in oncology, targeted therapies base on molecular profile of cancer, early detection of cancer via specialized imaging, drugs aimed at improving survival of HIV patients, and use of integrative therapies to reduce side effects related to cancer treatment.

Explore 311,636 research studies in all 50 states and in 209 countries. ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine.

Active Research Studies Website

The HIV Institute at the University of California San Diego is pleased to announce the Active Research Studies website, featuring a collection of HIV and HIV-related research at the University of California San Diego. 

Progress in treatment for HIV, hepatitis C, hepatitis B, tuberculosis, and other related conditions only occurs with the valuable contributions of individuals who enroll in research studies. These clinical research trials help improve the treatment and management of HIV and other infectio

Cannabis Effects on Antiretroviral Therapy, Pharmacokinetics, and Neurotoxicity

Status: Enrolling

Summary:

Are you HIV positive and on stable Antiretroviral Therapy (ART)? We want to

learn if cannabis has an effect on your ART regimen. If interested, give us a call and find

out if you are eligible. The #1 requirement is that you’re on HIV meds. Other requirements

will be reviewed over the phone. Hope to hear from you soon!*

In order to participate you must be*:

• Currently on a steady HIV treatment

• Cannabis and non-cannabis users

• Willing to do some concentration tests

For further details regarding this study, or other studies, please call (619) 543-5000 and ask to speak with a recruiter.

*Not all individuals are eligible to participate.

All information collected is kept strictly confidential.

Measurement of ART Drug Concentrations in Brain by 19f-MRS as an Indicator of Neurotoxicity

Status: Enrolling

Summary:

Participate in a one-time research visit looking at the effects of your current HIV medication

and your brain.

Study visit consists of:

• A brief medical interview

• A blood draw

• An MRI

Visit lasts about 4 hours.

Compensation of $120

Transportation provided (within San Diego County)

You may qualify if you are taking any of the following HIV medications*:

• Pifeltro (Doravirine)

• Emtriva (Emtricitabine)

• Tivicay, Juluca (Dolutegravir)

For further details regarding this study, or other studies, please call (619) 543-5000 and ask to speak with a recruiter.

Neuropathic Pain & Cannabis Study

• Effect of cannabis on HIV neuropathic pain

• 6 month +

• HIV+ & HIV-related Neuropathic Pain

• 2 components :

• Daily text messaging / surveys (6 months)

• Cannabis administration (3 office visits)

• Initial screen (1 hour)

• In-person medical screen (6-8 hours)

• If eligible, enroll in either or both

• Compensation up to $570

For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.

Nicotine and HIV Study

• Effects of nicotine on the brain

• 1 visit – baseline only – (8 hours)

• Some candidates may qualify: MRI / PET visits separately

• HIV+/-

• Current Smokers

• Initial screen (1 hour)

• 1 visit - Compensation up to $90

• Possible MRI and or PET scan addtional compensation up to $177.40

For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.

Health in Older Latinos Study

• Ethnic and racial differences in the cognitive effects of HIV

• 3visits -3years

• Latino HIV+/-

• Spanish or English

• Initial screen (1 hour)

• Compensation up to $305

For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.

Physical Activity and Diet Study

Status: Enrolling

Summary:

Participate in a 12-month research study that uses text messages to help people increase their physical activity and improve their diet.

In order to participate you must be*:

• HIV+

• 18+

• Able to speak and read English

• Able to eat walnuts

• Able to do moderate physical activity such as walking

Other information

• We compensate participants $35 to participate in a screening visit (about 1 hour).

• Participants who complete the 12-month study will be paid up to an additional $465

For further details regarding this study, or other studies, please call (619) 543-5000 and ask to speak with a recruiter.

*Not all individuals are eligible to participate.

All information collected is kept strictly confidential.

This study has been posted on clinicaltrials.gov. Click here to access this posting.

Tesamorelin Abdominal Fat Study

• Cognitive improvements from using Tesamorlin

• 1-year study

• HIV+ with abdominal fat 40 y/o

• Spanish or English

• Multiple In-person screening visits

• Immediate group or delayed group

• Daily Text messaging

• Self-administer medication for 6 months

• 5 study visits, plus phone visits

• Compensation up to $635 w/ optional LPs

For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.

Virtual Reality Assessment Study

• VR assessment for Cognitive and Balance

• 2.5-year study

• HIV+ 60+y/o

• Initial screen (1 - 1 1⁄2 hours)

• 8 visits over 2 years

• 5 HNRP visits – (full & partial visits)

• 3 SDSU visits for hearing tests

• Compensation up to $390

For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.

“A 16-Week Study Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo to treat HIV-Associated Distal Sensory Polyneuropathy (DSP) in Patients with HIV (PWH)” 

Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV. Abdominal fat accumulation is linked to memory and thinking difficulties, and previous studies have suggested that tesamorelin also may be beneficial for memory and thinking, but this has not been tested in HIV.

This is a randomized trial in which participants will have a 60% chance of initially receiving tesamorelin (the Immediate group) and a 40% chance of initially receiving no treatment (the Deferred group) for 6 months. Subsequently, those who initially received no treatment will receive tesamorelin and those who initially received tesamorelin will receive no treatment for 6 months.

This study includes text messaging, memory and thinking assessments, blood draws, and magnetic resonance imaging (MRI) scans of the head and abdomen.

Illuminate HTE Study

Illuminate HTE Study a Phase 3 clinical trial evaluating an oral, once-daily investigational medication, a fixed-dose combination of doravirine/islatravir (DOR/ISL), in participants with HIV-1 who are heavily treatment experienced and failing on their current antiretroviral therapy (ART).

DID YOU JUST GET TESTED FOR COVID-19 

but are not sick enough to be hospitalized?

Palmtree Clinical Research, Inc. (PCR, Inc.) is currently enrolling for a COVID-19 clinical trial. We are looking for patients who have recently tested positive for COVID-19.

This is an outpatient trial, 5 visits (3 in-clinic and 2 phone calls) over about a month period, with the Investigational Product being Camostat (PO, QID x 14 days).

You May Qualify If You

• Just received a POSITIVE COVID-19 test result or less than 3days ago 

• Are at least18 years old

• Do not need to be treated in the hospital right now

• Can come to the clinic to sign-up and complete 2 more visits

Have just one risk factor below along with a positive COVID-19 test: 

• Are age 65 or older

• Have diabetes mellitus (Type 1 or Type 2)

• Have high blood pressure

• Have chronic heart, lung, or liver disease, or 

• Are 35 lbs or more overweight

Participation Involves

• Taking tablets for 14 days of treatment

• Keeping a daily log of your temperature once a day

• Three (3) short clinic visits for nasal swabs and blood draws

PARTICIPANTS WILL BE COMPENSATED FOR THEIR PARTICIPATION

CALL OR EMAIL FOR MORE INFORMATION ABOUT THE CAMELOT TRIAL Please call: 760-778-7799 Email: contact@palmtreeclinical.com

555 E Tachevah Drive, Suite 1E-201, Palm Springs, CA 92262

(Located across from Desert Regional Hospital in the Las Palmas Medical Plaza)

Recruiting participants who have a current viral load >400 copies : Investigating PRO 140 subcutaneous injection once weekly combine with OBT in treatment experienced patients.

The GALACTIC-1 study will research a potential study drug that could offer benefit to patients with IPF. Thank you for considering participation in this trial.

– ACTG5391

 The study, “Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)” is a randomized evaluation of Doravirine vs. other INSTI among PWH who have gained weight during their current INSTI therapy. I am enclosing a summary of the protocol details. We would love it if you could share this information with your contacts in Palm Springs? We anticipate that the study will enroll rapidly, so I have included the study coordinator emails (George and Cristina) – feel free to reach out to any of us if you have questions. Interested people can be referred to George or Cristina for more information.

UCSD Live Healthy Study

Who can participate?

Persons living with HIV who smoke or recently quit smoking

What does participation involve?

Questionnaire (35-45 minutes).  Compensation is $30.

AND/OR

Focus Group (1-1.5 hours). Compensation is $35.How to participate?

All participation is remotePlease click this link to complete the eligibility screener:https://tinyurl.com/yyvhuahe

(If the link does not work, please copy and paste it into your web browser)

If you are eligible, you will be invited to complete the main survey.  Focus groups are conducted remotely via Zoom or phone.